For us at Transo-Pharm, supply continuity has always been part of our DNA and for our life saving Epinephrine it is truly a matter of the heart. In order to ensure a resilient supply chain for this API, we have already established a 2-year safety stock initiative in order to ensure availability of Epinephrine and to avoid shortages. We are proud to say, that we did not experience any supply problems during the last pandemic.
 
We are now taking the next step toward strengthening our security supply by establishing hameln rds s.r.o. in Modra, Slovakia, as a second manufacturing location. Transo-Pharm has qualified the site and the new CEPs for Epinephrine Base and Bitartrate have already been granted by EDQM (Adrenaline & Adrenaline tartrate) end of 2025. 
Important: We will submit an amendment to our US-DMF by April of this year to add hameln rds s.r.o. as an alternative site. 

If you have any further questions about our supply chain optimization project, please visit us at this year’s DCAT in New York. You can find us at the Lotte Hotel New York Palace from March 23 to 26, 2026.

Our Epinephrine product manager Jessica Ha looks forward to seeing you there. If you wish to make an appointment, please contact [email protected]

It has been three weeks now since the pharma world met in Milan for the CPHI 2024.

Three intensive days in this beautiful city were worth the efforts as they brought a lot of ideas to light, which we are now working on.
 
The whole Transo-Pharm team enjoyed meeting up with our friends and partners  – be it at a table at the Transo-Pharm booth or during our Happy Hour event with a glass of wine in our hands.
 
We are already looking forward to seeing you all again in Frankfurt in 2025.

Over a decade has passed since we acquired the Epinephrine (Adrenaline) business from Boehringer Ingelheim. At Transo-Pharm, we didn’t just take over the business — we made a commitment to ensuring a secure supply chain for our customers. We've gone even further by integrating upstream to become less dependent on external suppliers for starting materials. Throughout the transition, we consistently provided bridging stock on time and streamlined the regulatory process for our valued partners.

​Discover the incredible journey we've been on...

In the past we have often heard about shortages of products containing the active ingredient Epinephrine; also known as Adrenaline. But taking a closer look at it one could always identify the real cause. It was either a manufacturer withdrawing their pharmaceutical formulation from the market or a supply chain issues related to medical device needed for injecting the finished dosage.
 
Transo-Pharm´s robust supply chain and our 2-year safety stock have always and will always ensures the availability of Epinephrine, dispelling supply shortage fears.

Dear Customers,
 
On May 25th we informed you about the fire accident at our Contract Manufacturer Syn-Tech in Taiwan.
 
We are happy to inform you that the next production campaign for Epinephrine and Epinephrine bitartrate started – only 3 weeks after the incident.
 
Thanks to the Syn-Tech colleagues for this tremendeous effort and excellent support during these difficult weeks.
 
Needless to say, there are no delays in deliveries as we are still supplying the API’s from our stock in Hamburg/Germany.

Dear Customers,
 
We regret to inform you that Syn-Tech Chem. & Pharm., Co Ltd. had a fire accident on May 20, 2021. Fortunately, nobody of the employees or the firefighters were injured.
 
The production facility where Epinephrine and Epinephrine bitartrate are produced are not affected at all.
​The same applies to raw & starting material warehouse, finished product warehouse and QA/QC labs. Nevertheless, a detailed review and investigation is currently underway.
 
Due to our extensive stockpiling program at our German site, Transo-Pharm can easely compensate such an event and can continue the supply of both API’s according to the existing demands and forecasts.
 
Please be assured that we continuously keep you updated on the status at our partner in Taiwan.